Complete remission of rare adenocarcinoma of the oropharynx with <scp>APCEDEN</scp><sup>®</sup> (dendritic cell‐based vaccine): a case report

Kumar, Chaitanya; Kohli, Sandeep; Chiliveru, Srikanth; Jain, Minish; Sharan, Bandana

doi:10.1002/ccr3.1169

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The autologous DC vaccine APCEDEN has been reported as safe and shown significant improvement in the quality of life of cancer patients. A clinical trial conducted in India described OS benefit of 397 days for patients with solid malignancies after receiving APCEDEN treatment [14,23,24]. Here, we describe a case of prostate cancer with metastases.…”

Section: Discussionmentioning

confidence: 96%

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN® in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-γ, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). This case demonstrates the potential efficacy of dendritic cell immunotherapy, showing a potent antitumor activity by enhancing the host immune responses, and improving quality of life.

show abstract

Section: Discussionmentioning

confidence: 96%

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics

Dwivedi,

Jain,

Gupta

et al. 2024

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics

et al. 2023

View full text Add to dashboard Cite

Background & aim: Dendritic cell (DC)-based immunotherapy modulates a patient's immune system for recognition and subsequent removal of tumor cells. DC-mediated anticancer therapy has been considered in several studies/ongoing trials for multiple types of cancer. Our aim is to describe the potential and current status of DC-based immunotherapy in oral cancer therapeutics. Materials & methods: An internet-based literature search with relevant search terms from 2012 to 2022 post-screening resulted in 58 articles that were considered for systematic review. Results & conclusion: Evaluation of DC based immunotherapy exploiting the critical immune cells in well-equipped laboratories with adequately trained and skilled experts along with a synergistic approach that is affordable and approachable to the patients can prove as an efficient anticancer therapy.

show abstract

Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN^® (dendritic cell‐based vaccine): a case report

Cited by 3 publications

References 26 publications

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy

Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics

Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics

Contact Info

Product

Resources

About

Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN® (dendritic cell‐based vaccine): a case report

Cited by 3 publications

References 26 publications

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ® in Combination With Chemotherapy

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ® in Combination With Chemotherapy

Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics

Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics

Contact Info

Product

Resources

About

Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN^® (dendritic cell‐based vaccine): a case report

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy